CA-TALKDESK
3.6.2024 15:01:26 CEST | Business Wire | Press release
Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today launched its latest annual Talkdesk Global Contact Center Key Performance Indicator (KPI) Benchmarking report. Announced this week at Customer Contact Week Las Vegas 2024, the report measures five traditional contact center performance metrics and indicates that amid surging inbound call volumes in 2023, AI helps organizations improve speed to answer, maintain service levels, and more.
The proprietary global data—gathered from across a wide range of industries, company sizes, and locations in 2023—is designed to help contact center leaders successfully navigate industry changes, especially the implications of generative AI (GenAI) on contact center operations and CX delivery. Moreover, the report contains six months of data since Talkdesk layered GenAI across the entire contact center platform, including its flagship Talkdesk CX Cloud™ and Industry Experience Clouds.
While Talkdesk has been an AI innovator since 2018, GenAI radically changed the contact center landscape in 2023. The report will help contact center leaders compare their performance against peers and understand how they can best implement AI and GenAI solutions in order to excel in core contact center competencies.
Among the KPI benchmarks’ insight into the performance and opportunities for success in contact centers, key findings include:
As call volumes increase, KPI indicators show AI offers a path to improved speed to answer and service levels.
- Total inbound calls increased 21% to 390 million in 2023 across Talkdesk customers. In a positive outlook for rising AI usage, speed to answer improved significantly – down 13% to an average of 8.7 seconds – and service level improved slightly to 75.61%.
- While recruitment and attrition were challenges in 2023, AI-powered self-service solutions helped handle a portion of the large volumes of calls despite labor shortages. These results indicate that AI is enabling organizations to engage with customers faster.
Human agents remain critical to the contact center.
- The role of the agent is still mission-critical. With inbound call volumes reaching over 390 million and the average talk time hovering around 2 minutes and 50 seconds, the data implies human agents will likely focus on handling more complex issues and customers who would rather have a human resolve their queries than AI.
Industry-specific contact center solutions correlate with higher service levels.
- While the average service level was maintained from 2022 to 2023 (75.4% in 2022 vs. 75.6% in 2023), some industries achieved higher service levels, including retail and consumer goods (RCG) at 78.5%. Organizations that deploy industry-tailored solutions, like Talkdesk Autopilot for Retail, Banking, and Healthcare, can accelerate contact center transformation with AI. The data implies industries can better address vertical-specific CX queries due to these tailored solutions.
To explore more data findings and examples from organizations seeing success today by leveraging AI and automation tools in the contact center – including results of 90%+ service levels – download the 2024 Talkdesk Global Contact Center KPI Benchmarking Report here.
Supporting Quotes
Neville Letzerich, chief marketing officer at Talkdesk, said: “Contact center KPI benchmarking helps center managers determine best practices, critically evaluate their business, and implement changes to be more competitive. Correlations between AI adoption and traditional contact center KPI performance enables decision makers to intelligently invest in technology solutions that meet their goals and ensure they keep pace with industry standards on AI.”
Crendal Kear, senior vice president of Customer Success at Talkdesk, commented: “As contact center managers operate in a radically changing, increasingly competitive landscape, benchmarking KPI data is invaluable to understand how their center operations measure up. Our customers have different goals, but we believe that learning from the collective experience is important as it reveals opportunities to prioritize success that likely wouldn’t surface from internal reflection.”
About Talkdesk
Talkdesk® is on a mission to rid the world of bad customer experience. With our cloud-native, generative AI-powered CX platform, purpose-built industry solutions, and extensible AI offerings, we empower enterprises in the cloud and on-premises to deliver exceptional customer experiences that make them more competitive, grow revenue, reduce costs, and provide operational efficiencies. With specialized workflows and integrations delivered out of the box for our Industry Experience Clouds, Talkdesk accelerates value for our customers faster and more simply than legacy or one-size-fits-all solutions.
Partnering with enterprises globally, we deliver continuous innovation and breakthrough results. Our commitment to reliability and security, paired with our track record of delivering on promises, sets us apart in the industry. Elevate customer experiences, streamline operations, and increase revenue with Talkdesk. Companies that love their customers use Talkdesk.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603611611/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
